164 related articles for article (PubMed ID: 32471831)
1. Reply to Siniorakis et al., "COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure".
Fedson DS; Opal SM; Rordam OM
mBio; 2020 May; 11(3):. PubMed ID: 32471831
[No Abstract] [Full Text] [Related]
2. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
Siniorakis E; Arvanitakis S; Nikolopoulos I; Elkouris M
mBio; 2020 May; 11(3):. PubMed ID: 32444383
[No Abstract] [Full Text] [Related]
3. Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.
Lévy BI; Fauvel JP;
Arch Cardiovasc Dis; 2020; 113(8-9):572-578. PubMed ID: 32863157
[TBL] [Abstract][Full Text] [Related]
4. Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).
Singh AK; Gupta R; Misra A
Diabetes Metab Syndr; 2020; 14(5):729. PubMed ID: 32473904
[No Abstract] [Full Text] [Related]
5. Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
Turgeon RD; Zieroth S; Bewick D; Chow CM; Clarke B; Cowan S; Fordyce CB; Fournier A; Gin K; Gupta A; Hardiman S; Jackson S; Lau B; Leong-Poi H; Mansour S; Marelli A; Quraishi AR; Roifman I; Ruel M; Sapp J; Singh G; Small G; Virani S; Wood DA; Krahn A
Can J Cardiol; 2020 Aug; 36(8):1180-1182. PubMed ID: 32502522
[No Abstract] [Full Text] [Related]
6. The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic.
Augoustides JGT
J Cardiothorac Vasc Anesth; 2020 Jul; 34(7):1717-1719. PubMed ID: 32360010
[No Abstract] [Full Text] [Related]
7. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.
Speth RC
Drug Dev Res; 2020 Sep; 81(6):643-646. PubMed ID: 32304146
[No Abstract] [Full Text] [Related]
8. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?
Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G
J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372
[TBL] [Abstract][Full Text] [Related]
9. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Danser AHJ; Epstein M; Batlle D
Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
[TBL] [Abstract][Full Text] [Related]
10. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
[No Abstract] [Full Text] [Related]
11. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H
Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070
[No Abstract] [Full Text] [Related]
12. Renin--angiotensin system blockers and the risk of critical or fatal coronavirus disease 2019 in African Americans.
Thomopoulos C; Michalopoulou H
J Hypertens; 2020 Dec; 38(12):2384-2386. PubMed ID: 33149061
[No Abstract] [Full Text] [Related]
13. Renin-Angiotensin-Aldosterone System Inhibitors Impact on COVID-19 Mortality: What's Next for ACE2?
Patel AB; Verma A
Clin Infect Dis; 2020 Nov; 71(16):2129-2131. PubMed ID: 32442259
[No Abstract] [Full Text] [Related]
14. [Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].
Mareev YV; Mareev VY
Kardiologiia; 2020 Apr; 60(4):4-9. PubMed ID: 32394850
[TBL] [Abstract][Full Text] [Related]
15. Reply to: 'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19'.
Zheng YY; Ma YT; Zhang JY; Xie X
Nat Rev Cardiol; 2020 May; 17(5):313-314. PubMed ID: 32231330
[No Abstract] [Full Text] [Related]
16. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA
Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565
[TBL] [Abstract][Full Text] [Related]
17. The dilemma of renin-angiotensin system inhibitors in coronavirus disease 2019 (COVID-19): insights into lung fluid handling and gas exchange in heart failure patients.
Guazzi M; Moroni A
Eur J Heart Fail; 2020 Jun; 22(6):926-928. PubMed ID: 32438449
[No Abstract] [Full Text] [Related]
18. Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Mackey K; Kansagara D; Vela K
Ann Intern Med; 2020 Nov; 173(9):W147-W148. PubMed ID: 32956599
[No Abstract] [Full Text] [Related]
19. Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?
Henry RA
CMAJ; 2020 Jun; 192(26):E728. PubMed ID: 32601254
[No Abstract] [Full Text] [Related]
20. Response by Gheblawi et al to Letter Regarding Article, "Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2".
Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY
Circ Res; 2020 Jul; 127(2):e46-e47. PubMed ID: 32614719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
